Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group study A5267

BACKGROUND: Drug-drug interactions complicate management of co-infection with HIV-1 and Mycobacterium tuberculosis. Bedaquiline (formerly TMC207), an investigational agent for the treatment of tuberculosis, is metabolized by cytochrome P450 (CYP) 3A which may be induced by the antiretroviral drug ef...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Dooley, Kelly E, Park, Jeong-Gun, Swindells, Susan, Allen, Reena, Haas, David W., Cramer, Yoninah, Aweeka, Francesca, Wiggins, Ilene, Gupta, Amita, Lizak, Patricia, Qasba, Sonia, van Heeswijk, Rolf, Flexner, Charles
Format: Artigo
Idioma:Inglês
Publicat: 2012
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3302922/
https://ncbi.nlm.nih.gov/pubmed/22126739
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/QAI.0b013e3182410503
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars